Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 according to data from Phase III trials conducted on 25,800 participants across India.
The data was submitted to the DCGI over the weekend.
#BharatBiotech #Covaxin #Covid19
Bharat Biotech has submitted Phase 3 clinical trial data for its Covid-19 vaccine, Covaxin, to the Drug Controller General of India..
The screening of children for clinical trials of Covaxin will start at AIIMS in Delhi from today, days after similar trials started..
